Meckler Jeffrey A 4

What Happened
Jeffrey A. Meckler, a director of Travere Therapeutics (TVTX), exercised stock options and sold the resulting shares on May 4, 2026. He exercised 8,000 option shares at an exercise price of $16.33 (costing $130,640) and sold those 8,000 shares in an open-market sale at $45.00 per share, generating $360,000. The filings also record an 8,000-share derivative disposition (reported at $0.00), reflecting the option conversion/settlement.

Key Details

• Transaction date: May 4, 2026; Form 4 filed May 6, 2026 (file appears timely).
• Exercise: 8,000 shares exercised at $16.33 = $130,640 paid.
• Sale: 8,000 shares sold open-market at $45.00 = $360,000 proceeds.
• Additional derivative entry: 8,000 shares reported as disposed at $0.00 (related to the option conversion).
• Footnotes: Sale executed under a written Rule 10b5-1(c) trading plan adopted Nov 17, 2025; the option granted May 18, 2016 is fully vested and expires May 18, 2026.
• Shares owned after the transactions: not specified in the provided filing details.

Context
This was an exercise-plus-sale completed the same day (common when insiders exercise options and immediately sell shares to cover costs or diversify). The sale was conducted under a pre-established 10b5-1 plan, which is a prearranged trading program that can indicate the sale was planned in advance rather than a discretionary decision made that day. This is a sale by a director (not a purchase), which is typically considered routine insider liquidity rather than a direct bullish signal.